NEW YORK (GenomeWeb News) – Metabolon today said that it has completed its acquisition of Lipomics Technologies for an undisclosed amount.
Lipomics' laboratory facilities will remain at the company's headquarters in Sacramento, Calif., while Metabolon will keep its headquarters and laboratories in Research Triangle Park, NC. Steven Watkins, the founder of Lipomics, is joining Metabolon as chief technology officer.
The combined company now has 140 employees and 450 clients.
Lipomics was acquired by Tethys Bioscience in 2008, but it is unclear if Lipomics was still part of Tethys at the time of the deal announced today. Metabolon did not respond to messages seeking clarification.
The acquisition merges Metabolon's metabolomics technology with Lipomics' TrueMass profiling lipids technology platform. According to Lipomics' website, the platform provides quantitative measurements of metabolites, including fatty acids, acylcarnitines, sterols, amino acids, bile acids, and eicosanoids.
Michael Milburn, CSO of Metabolon, said in a statement that the combination of technologies "will deliver new and improved diagnostic products and personalized medicine solutions for unmet needs, particularly in metabolic disease and cancer."
Metabolon CEO John Ryals added that in addition to a metabolomics-based diagnostic test for type 2 diabetes already on the market, the company expects to launch other diagnostic products for diseases related to obesity and cancer in 2013.